SG11201805162VA - Plasmid constructs for heterologous protein expression and methods of use - Google Patents
Plasmid constructs for heterologous protein expression and methods of useInfo
- Publication number
- SG11201805162VA SG11201805162VA SG11201805162VA SG11201805162VA SG11201805162VA SG 11201805162V A SG11201805162V A SG 11201805162VA SG 11201805162V A SG11201805162V A SG 11201805162VA SG 11201805162V A SG11201805162V A SG 11201805162VA SG 11201805162V A SG11201805162V A SG 11201805162VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rule
- pct
- applicant
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 1111111101111011101010111110101111101110101101111111111111101111101111011111 International Bureau 0.. .... .. (10) International Publication Number (43) International Publication Date ..... ...r .....1 WO 2017/106795 Al 22 June 2017(22.06.2017) WIPO I PCT (51) International Patent Classification: (72) Inventor: PIERCE, Robert H.; 877 Island Avenue, Unit C12N 15/85 (2006.01) A61P 35/00 (2006.01) 1002, San Diego, CA 92101 (US). C12N 15/79 (2006.01) A61K 48/00 (2006.01) C12N 15/63 (2006.01) A61K 39/39 (2006.01) (74) Agent: MOHAN-PETERSON, Sheela; 5820 Nancy C12N 15/09 (2006.01) A61K 39/00 (2006.01) Ridge Drive, San Diego, CA 92121 (US). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/US2016/067388 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (22) International Filing Date: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, 16 December 2016 (16.12.2016) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (25) Filing Language: English KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (26) Publication Language: English MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (30) Priority Data: RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, 62/269,702 18 December 2015 (18.12.2015) US TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, 62/375,245 15 August 2016 (15.08.2016) US ZA, ZM, ZW. (71) Applicant: ONCOSEC MEDICAL INCORPORATED (84) Designated States (unless otherwise indicated, for every [US/US]; 5820 Nancy Ridge Drive, San Diego, CA 92121 kind of regional protection available): ARIPO (BW, GH, (US). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (72) Inventors; and TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicants : CAMPBELL, Jean [US/US]; 839 Northeast TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, 92nd St., Seattle, WA 98115 (US). CANTON, David A. DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, [US/US]; 13023 Neddick Ave., Poway, CA 92064 (US). LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). [Continued on next page] (54) Title: PLASMID CONSTRUCTS FOR HETEROLOGOUS PROTEIN EXPRESSION AND METHODS OF USE (57) : Provided are plasmid vector constructs encoding multiple immunomod- ulatory proteins where each protein or component thereof can be expressed utiliz- ing appropriate promotors and/or transla- tion modifiers. Additional immunomodu- latory proteins and genetic adjuvants con- taining shared tumor antigens can be added to further therapeutic potential as well as allow tracking of therapeutic treatment. pOMI A, 112 Also provides are methods of expressing the plasmid constructs. 11 ir) CT IN FIG .I 11 Ir ---- 11 ei O WO 2017/106795 Al MIDEDIMOMOIDEIHMEMOMOMENOMMODEVOIS Declarations under Rule 4.17: Published: — as to applicant's entitlement to apply for and be granted — with international search report (Art. 21(3)) a patent (Rule 4.17(0) — before the expiration of the time limit for amending the — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562269702P | 2015-12-18 | 2015-12-18 | |
US201662375245P | 2016-08-15 | 2016-08-15 | |
PCT/US2016/067388 WO2017106795A1 (en) | 2015-12-18 | 2016-12-16 | Plasmid constructs for heterologous protein expression and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201805162VA true SG11201805162VA (en) | 2018-07-30 |
Family
ID=59057754
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913163PA SG10201913163PA (en) | 2015-12-18 | 2016-12-16 | Plasmid constructs for heterologous protein expression and methods of use |
SG11201805162VA SG11201805162VA (en) | 2015-12-18 | 2016-12-16 | Plasmid constructs for heterologous protein expression and methods of use |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913163PA SG10201913163PA (en) | 2015-12-18 | 2016-12-16 | Plasmid constructs for heterologous protein expression and methods of use |
Country Status (10)
Country | Link |
---|---|
US (2) | US11713467B2 (en) |
EP (1) | EP3390643B8 (en) |
JP (2) | JP7079729B2 (en) |
KR (1) | KR20190031424A (en) |
CN (1) | CN109642240A (en) |
AU (2) | AU2016369608B2 (en) |
CA (1) | CA3009123A1 (en) |
IL (2) | IL299646A (en) |
SG (2) | SG10201913163PA (en) |
WO (1) | WO2017106795A1 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3286311T3 (en) | 2015-03-26 | 2021-09-13 | Oncosec Medical Incorporated | Method for the treatment of malignancies |
AU2017268399B2 (en) | 2016-05-18 | 2023-01-12 | Modernatx, Inc. | mRNA combination therapy for the treatment of cancer |
AU2017331275A1 (en) * | 2016-09-23 | 2019-05-16 | Oncosec Medical Incorporated | Modulating responses to checkpoint inhibitor therapy |
CN111133109A (en) * | 2017-06-13 | 2020-05-08 | 昂科赛克医疗公司 | Multi-gene constructs for immunomodulating protein expression and methods of use thereof |
GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
CN107164538B (en) * | 2017-07-11 | 2021-03-02 | 复旦大学附属华山医院 | Internal reference amplification primer composition for detecting CALR gene mutation and amplification system thereof |
RU2020132924A (en) * | 2018-03-08 | 2022-04-11 | Рубиус Терапьютикс, Инк. | THERAPEUTIC CELL SYSTEMS AND METHODS FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASES |
TW202039537A (en) * | 2018-11-27 | 2020-11-01 | 美商昂科賽克醫療公司 | Plasmid constructs for treating cancer and methods of use |
CA3122395A1 (en) * | 2018-12-11 | 2020-06-18 | Oncosec Medical Incorporated | Multigene construct for immune-modulatory protein expression and methods of use |
KR102524247B1 (en) * | 2018-12-21 | 2023-04-21 | 가톨릭대학교 산학협력단 | p40-EBI3 COMPLEX AND USES THEREOF |
US20210047425A1 (en) | 2019-08-12 | 2021-02-18 | Purinomia Biotech, Inc. | Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells |
JP2022549138A (en) | 2019-09-18 | 2022-11-24 | インターガラクティック セラピューティクス インコーポレイテッド | Synthetic DNA vectors and their uses |
TW202128775A (en) | 2019-10-16 | 2021-08-01 | 英商阿法克塔生命科學有限公司 | Pd-l1 inhibitor - tgfβ inhibitor bispecific drug moieties |
GB202101299D0 (en) | 2020-06-09 | 2021-03-17 | Avacta Life Sciences Ltd | Diagnostic polypetides and methods |
CN112126644B (en) * | 2020-11-25 | 2021-03-12 | 北京立康生命科技有限公司 | mRNA (messenger ribonucleic acid) transcribed outside cells under independent cap structure, presenting cell and application |
EP4288140A1 (en) | 2021-02-05 | 2023-12-13 | Iovance Biotherapeutics, Inc. | Adjuvant therapy for cancer |
KR102393402B1 (en) * | 2021-03-26 | 2022-05-04 | (주)와이디생명과학 | Composition for the preventing or treating cancer comprising an expression vector for dual genes |
WO2022234003A1 (en) | 2021-05-07 | 2022-11-10 | Avacta Life Sciences Limited | Cd33 binding polypeptides with stefin a protein |
WO2023057567A1 (en) | 2021-10-07 | 2023-04-13 | Avacta Life Sciences Limited | Pd-l1 binding affimers |
TW202332694A (en) | 2021-10-07 | 2023-08-16 | 英商阿凡克塔生命科學公司 | Serum half-life extended pd-l1 binding polypeptides |
CN116510022B (en) * | 2022-11-23 | 2023-12-05 | 武汉滨会生物科技股份有限公司 | Anti-tumor composition, recombinant plasmid composition and application thereof |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL112820A0 (en) | 1994-03-07 | 1995-05-26 | Merck & Co Inc | Coordinate in vivo gene expression |
EP0803573A1 (en) * | 1996-04-25 | 1997-10-29 | Gesellschaft für Biotechnologische Forschung mbH (GBF) | Polycistronic expression construct with cytokines for multivalent vaccines |
US5891432A (en) * | 1997-07-29 | 1999-04-06 | The Immune Response Corporation | Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same |
AU4250600A (en) | 1999-04-21 | 2000-11-02 | Genzyme Corporation | Adenoviral vectors having nucleic acids encoding immunomodulatory molecules |
AU6120600A (en) * | 1999-06-08 | 2000-12-28 | Uab Research Foundation | Herpes simplex virus expressing foreign genes and method for treating cancers therewith |
WO2001029233A2 (en) | 1999-10-20 | 2001-04-26 | The Johns Hopkins University School Of Medicine | Chimeric immunogenic compositions and nucleic acids encoding them |
US6714816B1 (en) * | 2000-02-22 | 2004-03-30 | University Of South Florida | Electroporation and electrophoresis system and method for achieving molecular penetration into cells in vivo |
CA2402213C (en) * | 2000-03-15 | 2012-08-07 | Pohang University Of Science And Technology | Genes of il-12p40 subunit mutated for improving the activity of il-12 and use thereof for dna vaccine adjuvant |
US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
DE10248141B4 (en) | 2002-10-11 | 2007-04-19 | Universitätsklinikum Hamburg-Eppendorf | Nucleic acids and their use for gene therapy |
EA200501937A1 (en) | 2003-05-30 | 2006-08-25 | Университет Южной Флориды | METHOD OF TREATMENT OF MALIGNANT TUMORS |
US8802643B1 (en) * | 2003-05-30 | 2014-08-12 | University Of South Florida | Method for the treatment of malignancies |
DE102005055128B4 (en) * | 2005-11-15 | 2015-04-02 | Universität Rostock | Viral vector, its use for the treatment of hepatocellular carcinoma and pharmaceutical agents comprising the vector |
WO2008046251A1 (en) | 2006-10-19 | 2008-04-24 | Sunbio Biotech Pharmaceuticals(Tianjin) Co., Ltd. | Fusion proteins containing n domain of human calreticulin and human papillomavirus type 16 e6 or e7 and uses thereof |
JP5415283B2 (en) | 2007-02-07 | 2014-02-12 | グラダリス インク. | Methods and compositions for modulating sialic acid production and treating hereditary inclusion body myopathy |
KR100911624B1 (en) * | 2007-05-14 | 2009-08-12 | 연세대학교 산학협력단 | Methods for Effectively Coexpressing ????? and ????? |
NZ616254A (en) | 2007-06-27 | 2015-04-24 | Us Sec Dep Of Health And Human Services | Complexes of il-15 and il-15ralpha and uses thereof |
CA2739902A1 (en) | 2008-10-08 | 2010-04-15 | Intrexon Corporation | Engineered cells expressing multiple immunomodulators and uses thereof |
US10266850B2 (en) | 2012-05-25 | 2019-04-23 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
CA2946407A1 (en) | 2014-04-25 | 2015-10-29 | Strike Bio, Inc. | Multiple targeted rnai for the treatment of cancers |
CA2981474A1 (en) | 2015-03-31 | 2016-10-06 | Oncosec Medical Incorporated | Systems and methods for improved tissue-sensing based electroporation |
WO2017214262A1 (en) | 2016-06-07 | 2017-12-14 | The Pacific Heart, Lung, & Blood Institute | Compositions and methods for treating cancer |
CN111133109A (en) | 2017-06-13 | 2020-05-08 | 昂科赛克医疗公司 | Multi-gene constructs for immunomodulating protein expression and methods of use thereof |
-
2016
- 2016-12-16 IL IL299646A patent/IL299646A/en unknown
- 2016-12-16 SG SG10201913163PA patent/SG10201913163PA/en unknown
- 2016-12-16 CN CN201680081690.5A patent/CN109642240A/en active Pending
- 2016-12-16 JP JP2018532285A patent/JP7079729B2/en active Active
- 2016-12-16 SG SG11201805162VA patent/SG11201805162VA/en unknown
- 2016-12-16 US US16/062,983 patent/US11713467B2/en active Active
- 2016-12-16 EP EP16876875.2A patent/EP3390643B8/en active Active
- 2016-12-16 CA CA3009123A patent/CA3009123A1/en active Pending
- 2016-12-16 KR KR1020187020538A patent/KR20190031424A/en not_active Application Discontinuation
- 2016-12-16 AU AU2016369608A patent/AU2016369608B2/en active Active
- 2016-12-16 WO PCT/US2016/067388 patent/WO2017106795A1/en active Application Filing
-
2018
- 2018-06-14 IL IL260039A patent/IL260039B2/en unknown
-
2020
- 2020-09-25 US US17/032,034 patent/US20210062218A1/en active Pending
-
2022
- 2022-05-23 JP JP2022083896A patent/JP2022116129A/en active Pending
-
2023
- 2023-05-02 AU AU2023202722A patent/AU2023202722A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2017106795A1 (en) | 2017-06-22 |
SG10201913163PA (en) | 2020-03-30 |
AU2023202722A1 (en) | 2023-05-18 |
US20210062218A1 (en) | 2021-03-04 |
KR20190031424A (en) | 2019-03-26 |
CN109642240A (en) | 2019-04-16 |
JP2018537989A (en) | 2018-12-27 |
AU2016369608B2 (en) | 2023-02-02 |
IL260039A (en) | 2018-07-31 |
JP2022116129A (en) | 2022-08-09 |
US11713467B2 (en) | 2023-08-01 |
IL260039B2 (en) | 2023-06-01 |
EP3390643B8 (en) | 2023-08-02 |
CA3009123A1 (en) | 2017-06-22 |
AU2016369608A1 (en) | 2018-08-02 |
IL299646A (en) | 2023-03-01 |
EP3390643A4 (en) | 2019-08-28 |
EP3390643B1 (en) | 2023-06-28 |
EP3390643A1 (en) | 2018-10-24 |
JP7079729B2 (en) | 2022-06-02 |
US20190153469A1 (en) | 2019-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201805162VA (en) | Plasmid constructs for heterologous protein expression and methods of use | |
SG11201804814YA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201908391XA (en) | Methods for modulating an immune response | |
SG11201804373VA (en) | Compositions and methods for immunooncology | |
SG11201909203WA (en) | Tissue selective transgene expression | |
SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
SG11201811603WA (en) | Novel adeno-associated virus capsid proteins | |
SG11201809144XA (en) | Materials and methods for treatment of hemoglobinopathies | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201804647TA (en) | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | |
SG11201807366WA (en) | System and method for generating custom shoe insole | |
SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
SG11201804070XA (en) | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a | |
SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
SG11201806002SA (en) | Methods for extending the replicative capacity of somatic cells during an ex vivo cultivation process | |
SG11201811290VA (en) | Compositions and methods for the depletion of cd117+cells | |
SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
SG11201811232XA (en) | Treatment of amd using aav2 variant with aflibercept | |
SG11201805052YA (en) | Therapeutic methods using erythrocytes | |
SG11201408405WA (en) | Engineered three-dimensional connective tissue constructs and methods of making the same | |
SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
SG11201903167QA (en) | Compounds and methods for reducing atxn3 expression | |
SG11201810627UA (en) | Compositions and methods for the treatment of human papillomavirus (hpv)-associated diseases |